Biogen Net Income From Continuing Ops from 2010 to 2026
| BIIB Stock | USD 190.92 1.93 1.02% |
Net Income From Continuing Ops | First Reported 2000-03-31 | Previous Quarter 466.5 M | Current Value -48.9 M | Quarterly Volatility 465.3 M |
Check Biogen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biogen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 982.2 M, Interest Expense of 258.3 M or Selling General Administrative of 2.6 B, as well as many indicators such as Price To Sales Ratio of 2.5, Dividend Yield of 0.0028 or PTB Ratio of 1.34. Biogen financial statements analysis is a perfect complement when working with Biogen Valuation or Volatility modules.
Biogen | Net Income From Continuing Ops | Build AI portfolio with Biogen Stock |
Analyzing Biogen's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Biogen's current valuation and future prospects.
Latest Biogen's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Biogen Inc over the last few years. It is Biogen's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biogen's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Biogen Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 2,523,665,294 | |
| Geometric Mean | 2,176,901,554 | |
| Coefficient Of Variation | 57.06 | |
| Mean Deviation | 1,199,713,958 | |
| Median | 1,879,565,000 | |
| Standard Deviation | 1,439,951,533 | |
| Sample Variance | 2073460.4T | |
| Range | 5B | |
| R-Value | (0.01) | |
| Mean Square Error | 2211265.5T | |
| R-Squared | 0.0002 | |
| Significance | 0.96 | |
| Slope | (3,955,767) | |
| Total Sum of Squares | 33175366.7T |
Biogen Net Income From Continuing Ops History
About Biogen Financial Statements
Biogen stakeholders use historical fundamental indicators, such as Biogen's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Biogen investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biogen's assets and liabilities are reflected in the revenues and expenses on Biogen's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biogen Inc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 1.3 B | 1.2 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out the analysis of Biogen Correlation against competitors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. Projected growth potential of Biogen fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biogen assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.192 | Earnings Share 8.58 | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets |
Biogen Inc's market price often diverges from its book value, the accounting figure shown on Biogen's balance sheet. Smart investors calculate Biogen's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Biogen's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Biogen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biogen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.